Category Archives: M&A

Mystic moldy pizza: Food for thought from Allicense 2014

SAN FRANCISCO – When talking trends in biopharma there’s no shortage of metaphors – Tuesday’s health care debate, for example, went for the timely baseball terms, referencing singles and home runs – or oft-overused industry buzzwords, of which the recent…

Share

Is it Better to Forgive and Pharm-merge?

Aug. 5 was International Forgiveness Day, and the founding organization of this annual effort, Worldwide Forgiveness Alliance (WFA), says in its mission statement that a goal is to promote and publicize the research findings that show forgiveness creates better health,…

Share

The Pharm-eleon is Shedding its Pharma-saurus Skin Again

If the big pharmas are indeed dinosaurs, they have learned to do what their predecessors could not: survive! Pharma may be prehistoric in terms of age compared to biotech, but it maneuvers more like a velociraptor than lumbering brontosaurus, as…

Share

A Stifled U.S. Biotech Sector: Is it Too Late to Recover?

BOSTON ‑ Amid all of the excitement that comes with the biopharma industry’s largest annual gathering in Boston this week, I’m worried about the future. The U.S. has lost too much ground ‑ due to the obvious partisan gridlock in…

Share

Big Pharma’s Vanishing Act

It wasn’t exactly love at first sight back in 1976 when Genentech Inc. became of legal age to go forth and incorporate, but the platonic relationship between biotech and pharma has increasingly mellowed over the ensuing 36 years into an…

Share

And the Bio-Oscar Goes to . . .

I have a fondness for the movies and I perform a function in the biotechnology market, so it’s a bonus when I can combine the two. I’ve written about the correlation between the movie and drug businesses before, so indulge…

Share

Licensing or Acquisition? Big Pharma Shares How They (and YOU) Decide

When I was at the Biocom Global Life Science Partnering Conference last week, one of the more interesting debates I heard was about whether it’s better to in-license an asset or acquire the whole company. While every case is different…

Share